Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: re: Nobody wants to ask biajj ... Ok Steve, ok, you win
Bullet points as requested. Everyone who feels that this Board has failed to adequately represent PTSC please feel free to add to this list
  • Lack of adequate communication from Board to shareholders regarding what a reasonable investor would consider material information
  • Failure to appoint an independent party to third seat on the PDS review panel as required by vacated suit against TPL which appears at this point to only have been a cya for the Board of ptsc.
  • Failure to request of TPL Bankruptcy Committee and or Judge to place an injunction on TPL owners from dumping at fire sale prices the main asset of TPL and the only asset of PTSC. Committee and Judge apparently do not realize the true value of the MMP patents
  • Lack of adequate knowledge in where the patent licensing process is at any given time and is dependent on a private party to give them information on Patriots only asset thereby depending and trusting a party that they have sued (?) for being unreliable and deceptive.
  • Having compensation for Board members set by a shareholder who also happens to control the information they are required to have to be proper fiduciaries of our companies asset.
  • Lack of reasonableness in hiring a "full time" permanent CEO but maintaing an interim CEO at what any reasonable fiduciary would consider to be an unreasonable compensation package and annual bonus for minimal work performed.
  • Providing to shareholders statements regarding goals etc that they fail to follow through on. An example would be Flowers stating that with a win over HTC the company has a massive PR campaign set to start immediately. Waiting for an appeals process was never mentioned and though common with all litigation very seldom stops a public company from providing information to shareholders or potential investors.
  • Inadequate response time (or no response at all) to legitimate shareholders questions that have been submitted verbally and or in writing.
Share
New Message
Please login to post a reply